Reading the tape
NASDAQ: ICUI
ICU Medical, Inc.
Healthcare · Medical - Instruments & Supplies
Market Cap
$2.94B
52w High
$160.29
52w Low
$107.00
P/E
3,970.16
Volume
1.13K
Outstanding Shares
24.99M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -12.74%Revenue (TTM): -6.35%FCF (TTM): -28.15%P/FCF: 32nd pct
What changed
The stock fell 12.74% over the last year. Revenue declined 6.35% over the trailing twelve months. Operating margin moved from 1.8% to 2.8%. Free cash flow declined 28.15% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at 2.8%. Revenue declined 6.35% — this read reverses if that trend stabilizes. Free cash flow fell 28.15% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide.
CEOVivek Jain
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees15,000
IPO dateMar 31, 1992
Valuation
Forward P/E—
EV/EBITDA14.09
Enterprise value$4.6B
Stock splits
Mar 18, 2002↑ Forward
Every 2 shares became 3
Apr 1, 1993↑ Forward
Every 2 shares became 3
Profitability & growth
Revenue growth-14.21%
Gross margin36.81%▲6.15%vs FY2024
Operating margin2.8%▲165.90%vs FY2024
ROE0.03%▲100.58%vs FY2024
Analyst consensus
RatingBuy
Target price$163.50▲38.89%
9
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $1.78 · Revenue est $520.57M
View